Protagonist Therapeutics, Inc

(NASDAQ:PTGX)

Latest On Protagonist Therapeutics, Inc (PTGX):

Date/Time Type Description Signal Details
2023-05-26 01:04 ESTNewsProtagonist Therapeutics Sees Steady If Bumpy ProgressN/A
2023-05-24 20:54 ESTNewsProtagonist Therapeutics: All Quiet Heading Into An Important H2 2023N/A
2023-05-12 13:28 ESTNewsProtagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseasesN/A
2023-05-05 17:50 ESTNewsProtagonist GAAP EPS of -$0.67 in-lineN/A
2023-04-05 11:14 ESTNewsProtagonist Therapeutics prices $100M offeringN/A
2023-04-04 19:17 ESTNewsProtagonist falls on $100M public offeringN/A
2023-03-16 06:46 ESTNewsProtagonist GAAP EPS of -$0.69 misses by $0.10N/A
2023-03-09 21:16 ESTNewsProtagonist Therapeutics: More Good News Likely To ComeN/A
2023-03-07 23:28 ESTNewsJohnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidateN/A
2023-03-07 08:43 ESTNewsCDTX, PTGX and TAST among premarket gainersN/A
2022-11-08 17:47 ESTNewsProtagonist GAAP EPS of -$0.64 beats by $0.23N/A
2022-08-05 06:50 ESTNewsProtagonist GAAP EPS of -$0.84 beats by $0.10N/A
2022-06-15 13:34 ESTNewsProtagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - SlideshowN/A
2022-06-08 23:40 ESTNewsProtagonist: Too Many Red FlagsN/A
2022-06-01 03:40 ESTNewsProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022N/A
2022-05-05 08:14 ESTNewsProtagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65MN/A
2022-04-26 17:35 ESTNewsProtagonist hits 52-week low as Street reacts to data for ulcerative colitis candidateN/A
2022-04-26 01:38 ESTNewsProtagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitisN/A
2022-04-15 02:54 ESTNewsProtagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertideN/A
2022-03-29 08:38 ESTNewsAsif Ali is the new finance chief at Protagonist TherapeuticsN/A
2022-02-28 17:25 ESTNewsProtagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62MN/A
2022-02-01 13:28 ESTNewsProtagonist Is Still Being Undervalued Like There's Real RiskN/A
2021-12-10 01:25 ESTNewsProtagonist Therapeutics (PTGX) Investor Presentation - SlideshowN/A
2021-12-02 23:48 ESTNewsProtagonist chooses candidate to advance into phase 2 in collaboration with JanssenN/A
2021-11-15 11:02 ESTNewsPhase 2a data supports Protagonist genetic liver disease drug rusfertideN/A
2021-10-12 11:34 ESTNewsJ.P. Morgan upgrades Protagonist to overweight following clinical hold removalN/A
2021-10-11 16:22 ESTNewsProtagonist gains nearly double after FDA removes clinical hold on rusfertide programN/A
2021-10-11 16:21 ESTNewsProtagonist price target raised at Northland following removal of clinical holdN/A
2021-10-06 15:26 ESTNewsPTGX is at high risk of performing badlyN/A
2021-09-30 21:08 ESTNewsProtagonist Therapeutics: How To Buy The DipN/A
2021-09-28 00:11 ESTNewsWarning: PTGX has been downgraded to Very BearishN/A
2021-09-25 08:13 ESTNewsBELLUS Health, Akoya Biosciences lead weekly healthcare gainers; Protagonist trailN/A
2021-09-22 04:02 ESTNewsProtagonist loses more than half after FDA placed clinical hold on rusfertide studiesN/A
2021-09-22 04:01 ESTNewsBELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trailN/A
2021-09-22 04:00 ESTNewsProtagonist extends slide as regulatory setback prompts downgrade at JP MorganN/A
2021-09-22 03:59 ESTNewsWarning: PTGX has been downgraded to Very Bearish.N/A
2021-08-10 10:13 ESTNewsProtagonist Therapeutics resolves contract dispute with Zealand PharmaN/A
2021-07-21 20:41 ESTNewsDosing underway in Protagonist Therapeutics' early-stage study of PN-232N/A
2021-07-21 20:32 ESTNewsProtagonist wins FDA Breakthrough Therapy Designation for blood cancer therapyN/A
2021-07-21 20:24 ESTNewsProtagonist climbs on positive effect in mid-stage study for rusfertide in polycythemia veraN/A
2021-07-21 20:23 ESTNewsBiogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst actionN/A
2021-07-21 20:22 ESTNewsProtagonist Therapeutics slumps 7.5% on raising $100M via public offeringN/A
2021-07-21 20:22 ESTNewsRAPT, SIOX, ACHL and PTGX among after-hours moversN/A
2021-07-21 20:21 ESTNewsProtagonist Therapeutics secures $115M capital via equity raiseN/A
2021-07-21 20:16 ESTNewsProtagonist Therapeutics closes $132M capital raiseN/A
2021-05-05 01:39 ESTNewsProtagonist EPS beats by $0.03, beats on revenueN/A
2021-03-12 04:31 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 04:31 ESTAnalyst RatingThe Analyst Target Price has increased from $35.4 to $37.Buy
2021-03-11 12:47 ESTNewsProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 04:23 ESTEarnings EstimateAn EPS average of -$1.48 is estimated for the 2022 year.Sell

About Protagonist Therapeutics, Inc (PTGX):

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

See Advanced Chart

General

  • Name Protagonist Therapeutics, Inc
  • Symbol PTGX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2016-08-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.protagonist-inc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 37.31
  • Price/Book (Most Recent Quarter) 4.86
  • Enterprise Value Revenue 37.04
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.97
  • Next Year EPS Estimate -$2.12
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -231%
  • Operating Margin -225%
  • Return on Assets -17%
  • Return on Equity -37%
  • Revenue 28.63 million
  • Earnings Per Share -$2.74
  • Revenue Per Share $0.83
  • Gross Profit 28.63 million
  • Quarterly Earnings Growth 107.8%
View More

Highlights

  • Market Capitalization 1.36 billion
  • EBITDA -70271000
  • Analyst Target Price $37
  • Book Value Per Share $6.39
View More

Share Statistics

  • Shares Outstanding 43.81 million
  • Shares Float 27.88 million
  • % Held by Insiders 161%
  • % Held by Institutions 93.65%
  • Shares Short 2.77 million
  • Shares Short Prior Month 2.78 million
  • Short Ratio 8.34
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.55
  • 52 Week High $31.58
  • 52 Week Low $5.44
  • 50 Day Moving Average 26.03
  • 200 Day Moving Average 22.63
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Protagonist Therapeutics, Inc (PTGX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$5.65 million-$0.48-$0.48-0.61%
2020-09-302020-11-04$N/A-$0.21-$0.6165.71%
2020-06-302020-08-06$N/A-$0.59-$0.57-2.91%
2020-03-312020-05-07$3.65 million-$0.72-$0.69-4.05%
2019-12-312020-03-10$2.72 million-$0.63-$0.652.78%
2019-09-302019-11-06$4.14 million-$0.61-$0.7720.26%
2019-06-302019-08-07$-8189000-$1.18-$0.39-206.49%
2019-03-312019-05-08$1.56 million-$0.58-$0.56-4.5%
2018-12-312019-03-12$2.35 million-$0.57-$0.47-20.25%
2018-09-302018-11-06$6.12 million-$0.38-$0.37-1.79%
2018-06-302018-08-07$11.67 million-$0.41-$0.30-35.18%
2018-03-312018-05-09$10.78 million-$0.36-$0.24-50%
2017-12-312018-03-07$11.28 million-$0.15-$0.3455.88%
2017-09-302017-11-06$8.78 million-$0.29-$0.8163.98%
2017-06-302017-08-08$N/A-$0.89-$0.86-4.09%
2017-03-312017-05-10$N/A-$0.84-$0.67-26.32%
2016-12-312017-03-07$N/A-$0.67-$0.52-28.85%
2016-09-302016-11-14$N/A-$0.87-$0.64-35.94%
2016-06-302016-07-11$N/A-$40.89-$0.83-4826.51%

Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 19.49 million N/A N/A 18.77 million 15.91 million
Income Before Tax -18.89 million N/A N/A -19.9 million -16.65 million
Selling General Administrative 4.99 million N/A N/A 4.58 million 4.11 million
Gross Profit N/A N/A N/A N/A 2.72 million
Ebit -18.76 million N/A N/A -19 million -17.3 million
Operating Income -18.83 million N/A N/A -19.7 million -17.3 million
Income Tax Expense N/A N/A 1.13 million 176000 856000
Total Revenue 5.65 million N/A N/A 3.65 million 2.72 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net -9000 N/A N/A -490000 654000
Net Income From Continuing Operations -18.89 million N/A N/A -20.08 million -17.5 million
Net Income Applicable to Common Shares -18.89 million -7.76 million -19.42 million -20.08 million -17.5 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A -32.35 million
Change to Liabilities -13.18 million -5.87 million -1.57 million N/A -4.06 million
Total Cash Flow from Investing Activities -54.12 million -5.17 million 42.73 million N/A -32.04 million
Net Borrowings N/A -10.52 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A 25.24 million
Change to Operating Activities 1.85 million -590000 -679000 N/A 725000
Change in Cash N/A N/A N/A N/A -20.95 million
Total Cash from Operating Activities -16.29 million -21.48 million -15.85 million N/A -14.25 million
Depreciation N/A N/A N/A N/A 639000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 2.94 million
Other Cash Flow from Financing Activities N/A -7000 -7000 N/A N/A
Change to Net Income 1.97 million 3.18 million 2.62 million N/A 1.91 million
Capital Expenditures N/A N/A N/A N/A -309000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 44.86 million N/A N/A 72.24 million N/A
Total Stockholder Equity 279.61 million N/A N/A 62.67 million N/A
Other Current Liabilities 15.94 million 18.84 million N/A N/A N/A
Total Assets 324.47 million N/A N/A 134.9 million N/A
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 6.29 million 10000 N/A 10000 N/A
Retained Earnings -283.81 million -264.93 million -257.16 million -237.74 million N/A
Other Liabilities 121000 4.28 million 16.88 million 20.42 million N/A
Other Assets 450000 450000 450000 1.53 million N/A
Cash 117.36 million N/A N/A 60.22 million N/A
Total Current Liabilities 40.24 million 38.56 million N/A 36.37 million N/A
Other Stockholder Equity 28000 -88000 -208000 107000 N/A
Property, Plant & Equipment 1.46 million 6.69 million 7.06 million 7.38 million N/A
Total Current Assets 315.61 million 204.15 million N/A 125.99 million N/A
Long Term Investments 2 million N/A N/A N/A N/A
Net Tangible Assets 279.61 million 169.59 million 167.49 million 62.67 million N/A
Short Term Investments 188.45 million N/A N/A 57.3 million N/A
Long Term Debt N/A N/A N/A 9.83 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 24.31 million 2.8 million N/A 3.7 million N/A

Protagonist Therapeutics, Inc (PTGX) Chart:

Protagonist Therapeutics, Inc (PTGX) News:

Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protagonist Therapeutics, Inc (PTGX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-19300CALL0 0278.55TRUE00
2025-09-19350CALL0 0249.77TRUE00
2025-09-19400CALL0 0200.83TRUE00
2025-09-19450CALL0 0149.6TRUE00
2025-09-19500CALL0 097.76TRUE00
2025-09-19552.2CALL0 41880.95TRUE00
2025-09-19601.45CALL2 152264.19FALSE1.450
2025-09-19650.19CALL1 2657.35FALSE0.190
2025-09-19700CALL0 0192.3FALSE00
2025-09-19750CALL0 0329.71FALSE00
2025-09-19800CALL0 0365.79FALSE00
2025-09-19300PUT0 0716.76FALSE00
2025-09-19350PUT0 0595.4FALSE00
2025-09-19400PUT0 0491.21FALSE00
2025-09-19450.8PUT0 16398.41FALSE00
2025-09-19500.35PUT0 4112.55FALSE00
2025-09-19550.56PUT0 6095.37FALSE00
2025-09-19600PUT0 032.99TRUE00
2025-09-19650PUT0 00TRUE00
2025-09-19700PUT0 00TRUE00
2025-09-19750PUT0 00TRUE00
2025-09-19800PUT0 00TRUE00
2025-10-17200CALL0 44211.65TRUE00
2025-10-1722.531.5CALL0 1184.63TRUE00
2025-10-17250CALL0 0169.95TRUE00
2025-10-17300CALL0 0117.94TRUE00
2025-10-17350CALL0 2111.12TRUE00
2025-10-174018.5CALL0 673.77TRUE00
2025-10-174513.9CALL0 774.78TRUE00
2025-10-175010.55CALL0 2464.99TRUE00
2025-10-17556.7CALL300 56863.18TRUE-0.5-0.07
2025-10-17604CALL25 85861.54FALSE40
2025-10-17652.25CALL63 14161.36FALSE-0.1-0.04
2025-10-17701.15CALL0 369.82FALSE00
2025-10-17750.65CALL1 262.82FALSE0.650
2025-10-17800CALL0 0115.74FALSE00
2025-10-17850CALL0 1143.95FALSE00
2025-10-17200PUT0 0363.13FALSE00
2025-10-1722.50PUT0 0328.05FALSE00
2025-10-17250PUT0 0364.16FALSE00
2025-10-17300PUT0 44302.07FALSE00
2025-10-17350.2PUT0 0251.07FALSE00
2025-10-17400PUT0 19139.91FALSE00
2025-10-17452.3PUT0 30160.69FALSE00
2025-10-17501.45PUT0 4362.28FALSE00
2025-10-17552.8PUT0 11954.8FALSE00
2025-10-17600PUT0 249.69TRUE00
2025-10-17650PUT0 048.32TRUE00
2025-10-17700PUT0 044.41TRUE00
2025-10-17750PUT0 00TRUE00
2025-10-17800PUT0 00TRUE00
2025-10-17850PUT0 00TRUE00
2026-01-1622.50CALL0 0105.63TRUE00
2026-01-16250CALL0 093.95TRUE00
2026-01-16300CALL0 054.6TRUE00
2026-01-16350CALL0 060.49TRUE00
2026-01-164017.35CALL0 9455.9TRUE00
2026-01-16450CALL0 053.21TRUE00
2026-01-16508.2CALL0 2653.11TRUE00
2026-01-16555.6CALL0 648.47TRUE00
2026-01-16607.25CALL0 849.18FALSE00
2026-01-16650.95CALL0 147.19FALSE00
2026-01-16702.6CALL0 348.86FALSE00
2026-01-16751.7CALL0 449.67FALSE00
2026-01-16801.1CALL0 358.8FALSE00
2026-01-16850.75CALL0 160.93FALSE00
2026-01-1622.50PUT0 0211FALSE00
2026-01-16250.45PUT0 3191.54FALSE00
2026-01-16300.65PUT0 1159.1FALSE00
2026-01-16350.95PUT0 1132.47FALSE00
2026-01-16401.5PUT0 190.93FALSE00
2026-01-16452.95PUT0 161.32FALSE00
2026-01-16502.64PUT0 5048.11FALSE00
2026-01-16550PUT0 048.49FALSE00
2026-01-16606.28PUT0 045.26TRUE00
2026-01-16650PUT0 043.72TRUE00
2026-01-16700PUT0 048.2TRUE00
2026-01-16750PUT0 046.6TRUE00
2026-01-16800PUT0 047.01TRUE00
2026-01-16850PUT0 039.47TRUE00
2026-03-2022.533CALL0 2577.38TRUE00
2026-03-202527.5CALL0 2688.72TRUE00
2026-03-20300CALL0 069.39TRUE00
2026-03-20350CALL0 053.29TRUE00
2026-03-20400CALL0 048.73TRUE00
2026-03-20459.3CALL0 248.52TRUE00
2026-03-205014.5CALL0 148.41TRUE00
2026-03-20557.5CALL0 1544.93TRUE00
2026-03-20600CALL0 044.02FALSE00
2026-03-20650CALL0 043.44FALSE00
2026-03-20700CALL0 043.51FALSE00
2026-03-20752CALL0 343.85FALSE00
2026-03-20801.8CALL0 1446.11FALSE00
2026-03-20851.4CALL0 652.79FALSE00
2026-03-2022.50.5PUT0 1172.83FALSE00
2026-03-20250.8PUT0 1156.94FALSE00
2026-03-20300.8PUT0 1130.45FALSE00
2026-03-20350PUT0 096.81FALSE00
2026-03-20400PUT0 078.71FALSE00
2026-03-20452.1PUT0 246.69FALSE00
2026-03-20500PUT0 047.79FALSE00
2026-03-20550PUT0 043.71FALSE00
2026-03-20600PUT0 044.11TRUE00
2026-03-206520.7PUT0 142.52TRUE00
2026-03-20700PUT0 042.26TRUE00
2026-03-20750PUT0 040.77TRUE00
2026-03-20800PUT0 041.21TRUE00
2026-03-20850PUT0 041.18TRUE00
2026-04-17300CALL0 060.73TRUE00
2026-04-17350CALL0 054.54TRUE00
2026-04-17400CALL0 054.65TRUE00
2026-04-17450CALL0 051.07TRUE00
2026-04-17500CALL0 048.4TRUE00
2026-04-17559.6CALL0 244.44TRUE00
2026-04-17600CALL0 045.42FALSE00
2026-04-17654.63CALL0 5042.12FALSE00
2026-04-17700CALL0 040.58FALSE00
2026-04-17750CALL0 039.18FALSE00
2026-04-17802.1CALL0 241.52FALSE00
2026-04-17300PUT0 0123.19FALSE00
2026-04-17350PUT0 085.35FALSE00
2026-04-17401.55PUT0 262.85FALSE00
2026-04-17452.5PUT0 148.34FALSE00
2026-04-17500PUT0 044.9FALSE00
2026-04-17550PUT0 043.26FALSE00
2026-04-17600PUT0 040.46TRUE00
2026-04-17650PUT0 041.87TRUE00
2026-04-17700PUT0 039.42TRUE00
2026-04-17750PUT0 039.48TRUE00
2026-04-17800PUT0 041.89TRUE00

Latest PTGX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST13$7.08
Jun 13, 2022 7:59 PM EST8$7.07
Jun 13, 2022 7:59 PM EST1$7.07
Jun 13, 2022 7:59 PM EST14$7.07
Jun 13, 2022 7:59 PM EST34$7.09

Protagonist Therapeutics, Inc (PTGX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2018-09-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000018029279/0000000000-18-029279-index.htm
2019-11-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000019015720/0000000000-19-015720-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506619001298/0000315066-19-001298-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506620001141/0000315066-20-001141-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720008027/0000834237-20-008027-index.htm
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266419000928/0000902664-19-000928-index.htm
2020-05-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266420002197/0000902664-20-002197-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189518002281/0000921895-18-002281-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189519000465/0000921895-19-000465-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189520000521/0000921895-20-000521-index.htm
2018-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041318002140/0000930413-18-002140-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041319000575/0000930413-19-000575-index.htm
2018-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918005447/0001047469-18-005447-index.htm
2018-09-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/0001047469-18-006015-index.htm
2018-09-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918006444/0001047469-18-006444-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746919002642/0001047469-19-002642-index.htm
2019-10-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746919006014/0001047469-19-006014-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746919006551/0001047469-19-006551-index.htm
2020-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746920002368/0001047469-20-002368-index.htm
2020-05-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920002943/0001047469-20-002943-index.htm
2020-05-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920003025/0001047469-20-003025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049635/0001104659-18-049635-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/0001104659-18-049963-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465918057889/0001104659-18-057889-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918063178/0001104659-18-063178-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918066340/0001104659-18-066340-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918070107/0001104659-18-070107-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/0001104659-18-075322-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014250/0001104659-19-014250-index.htm
2019-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014317/0001104659-19-014317-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919017130/0001104659-19-017130-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465919024116/0001104659-19-024116-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027659/0001104659-19-027659-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027662/0001104659-19-027662-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919029003/0001104659-19-029003-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/0001104659-19-032445-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035338/0001104659-19-035338-index.htm
2019-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035942/0001104659-19-035942-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919044426/0001104659-19-044426-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919058437/0001104659-19-058437-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919060537/0001104659-19-060537-index.htm
2019-11-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465919065981/0001104659-19-065981-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/0001104659-19-068332-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919069217/0001104659-19-069217-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920021728/0001104659-20-021728-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/0001104659-20-024253-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031381/0001104659-20-031381-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031453/0001104659-20-031453-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920035420/0001104659-20-035420-index.htm
2020-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465920047714/0001104659-20-047714-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920058140/0001104659-20-058140-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920059922/0001104659-20-059922-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920067747/0001104659-20-067747-index.htm
2020-06-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1377121/000110465920070830/0001104659-20-070830-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920091424/0001104659-20-091424-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920094719/0001104659-20-094719-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920104437/0001104659-20-104437-index.htm
2020-10-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920111763/0001104659-20-111763-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920121408/0001104659-20-121408-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312518345594/0001193125-18-345594-index.htm
2019-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519015661/0001193125-19-015661-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519028285/0001193125-19-028285-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519040996/0001193125-19-040996-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312520038117/0001193125-20-038117-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037316/0001209191-18-037316-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/0001209191-18-037317-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/0001209191-18-037318-index.htm
2018-07-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118042575/0001209191-18-042575-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003141/0001209191-19-003141-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-01-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003645/0001209191-19-003645-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/0001209191-19-003994-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022776/0001209191-19-022776-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/0001209191-19-030616-index.htm
2019-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034081/0001209191-19-034081-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034082/0001209191-19-034082-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036195/0001209191-19-036195-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036203/0001209191-19-036203-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036204/0001209191-19-036204-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036207/0001209191-19-036207-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/0001209191-19-036211-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/0001209191-19-036214-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/0001209191-20-014088-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014090/0001209191-20-014090-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/0001209191-20-014092-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014097/0001209191-20-014097-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/0001209191-20-014100-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120023949/0001209191-20-023949-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120026593/0001209191-20-026593-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033016/0001209191-20-033016-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033020/0001209191-20-033020-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033022/0001209191-20-033022-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033026/0001209191-20-033026-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/0001209191-20-033031-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/0001209191-20-033032-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2020-08-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047233/0001209191-20-047233-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047246/0001209191-20-047246-index.htm
2018-08-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465918005609/0001214659-18-005609-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465919001113/0001214659-19-001113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465920001392/0001214659-20-001392-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000131924419000056/0001319244-19-000056-index.htm
2019-12-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315219019237/0001493152-19-019237-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315220002364/0001493152-20-002364-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000155837018006590/0001558370-18-006590-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/0001558370-18-006639-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018008657/0001558370-18-008657-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837019001853/0001558370-19-001853-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/0001558370-19-004481-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/0001558370-19-007515-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/0001558370-19-010201-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/0001558370-20-002334-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020005785/0001558370-20-005785-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/0001558370-20-009681-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020012597/0001558370-20-012597-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999518002437/9999999995-18-002437-index.htm
2019-11-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999519002648/9999999995-19-002648-index.htm

Protagonist Therapeutics, Inc (PTGX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-11CHAITAN PHD KHOSLADirectorSell2,499.0017.1942,952.060.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy562.005.092,860.581,175.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2020-03-12HAROLD E SELICKDirectorBuy12,000.006.7080,400.0015,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2019-02-28Suneel GuptaEVP Clinical OperationsBuy7,500.0017,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell2,580.007.7119,891.8024,178.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2020-08-11CHAITAN PHD KHOSLADirectorBuy2,499.001.894,723.112,499.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-02-28Samuel R SaksChief Development OfficerBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell198.008.151,613.7026,758.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2018-08-15Richard S. ShamesChief Medical OfficerBuy18,750.0026,956.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-15Thomas P. O'NeilChief Financial OfficerBuy21,100.0030,560.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-03-01Richard S. ShamesChief Medical OfficerSell657.008.035,275.7132,021.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-02-28Richard S. ShamesChief Medical OfficerBuy8,500.0032,678.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-04-01HAROLD E SELICKDirectorBuy3,310.001.314,336.103,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2018-08-15DINESH V PH D PATELPresident and CEOBuy82,050.00345,829.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell10,132.007.7178,117.72357,264.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell777.008.106,292.22367,396.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-01-11DINESH V PH D PATELPresident and CEOBuy22,344.001.1625,919.04368,173.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-02-06David Y LiuChief Scientific OfficerSell3,821.007.7429,561.5537,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-08-06DINESH V PH D PATELPresident and CEOSell10,792.008.8595,535.10374,792.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-11-26DINESH V PH D PATELPresident and CEOBuy4,000.001.164,640.00379,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-03-01DINESH V PH D PATELPresident and CEOSell2,183.008.0317,529.49383,831.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-02-28DINESH V PH D PATELPresident and CEOBuy28,750.00386,014.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy10,000.005.5555,500.00389,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2018-08-15David Y LiuChief Scientific OfficerBuy25,800.0040,828.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy20,000.005.65113,000.00409,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2020-03-12DINESH V PH D PATELPresident and CEOBuy18,344.001.1621,279.04429,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-20DINESH V PH D PATELPresident and CEOBuy10,000.001.8918,900.00439,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2019-12-03Suneel GuptaEVP Clinical OperationsBuy30,000.005.13153,900.0049,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-08-06David Y LiuChief Scientific OfficerSell3,395.008.8530,044.0549,802.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-03-01David Y LiuChief Scientific OfficerSell810.008.036,504.3051,197.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-02-28David Y LiuChief Scientific OfficerBuy15,000.0052,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy613.005.103,126.30613.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03Bryan GiraudoDirectorBuy8,000.005.7045,620.008,000.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm